

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. REDDY'S LABORATORIES, LTD. AND
DR. REDDY'S LABORATORIES, INC.,
Petitioners,

v.

INDIVIOR UK LIMITED,
Patent Owner.

Case No. IPR2016-01113
Patent No. 8,475,832

PATENT OWNER'S PRELIMINARY RESPONSE
PURSUANT TO 37 C.F.R. § 42.107

EXHIBIT LIST

Exhibit	Description
2001	Redline comparison of Teva IPR2016-00280 Petition and Dr. Reddy's IPR2016-01113 Petition
2002	Redline comparison of Teva IPR2016-00280 Declaration of Dr. Das and Dr. Reddy's IPR2016-01113 Declaration of Dr. Celik
2003	<i>Dr. Reddy's to acquire product portfolio from TEVA for US Market</i> , Press Release, Dr. Reddy's Laboratories Ltd., June 11, 2016
2004	Email from Dr. Reddy's counsel summarizing meet and confer teleconference conducted July 6, 2016
2005	Teva/Allergan Divestiture Products Table, Docket No. C-4589 (F.T.C. July 27, 2016)
2006	<i>FTC Requires Teva to Divest Over 75 Generic Drugs to Settle Competition Concerns Related to its Acquisition of Allergan's Generic Business</i> , Press Release, Federal Trade Commission (July 27, 2016), https://www.ftc.gov/news-events/press-releases/2016/07/ftc-requires-teva-divest-over-75-generic-drugs-rival-firms-settle
2007	PTAB Telephonic Conference Transcript, IPR2016-01111, IPR2016-01112, IPR2016-01113 (August 1, 2016)
2008	Carl O'Donnell, <i>Teva Pharm finalizing asset sales to clear Allergan deal - source</i> , Reuters (May 5, 2016), http://www.reuters.com/article/allergan-ma-teva-pharm-ind-assets-idUSL2N1820VD
2009	Nandita G. Das & Sudip K. Das, <i>Development of Mucoadhesive Dosage Forms of Buprenorphine for Sublingual Drug Delivery</i> , 11 Drug Delivery 89 (2004)
2010	Priya Batheja <i>et al.</i> , <i>Basic Biopharmaceutics of Buccal and Sublingual Absorption</i> , in <i>Enhancement in Drug Delivery</i> 175, 182 (Elka Touitou & Brian W. Barry eds. 2006)
2011	David S. Weinberg <i>et al.</i> , <i>Sublingual absorption of selected opioid analgesics</i> , 71 <i>Clinical Pharmacology & Therapeutics</i> 335 (1988)
2012	John Mendelson <i>et al.</i> , <i>Bioavailability of Sublingual Buprenorphine</i> , 37 <i>J. Clinical Pharmacology</i> 31 (1997)

Exhibit	Description
2013	Jinsong Hao & Paul W.S. Heng, <i>Buccal Delivery Systems</i> , 29(8) Drug Development & Industrial Pharmacy 821 (2003)
2014	S.A. Robertson, <i>PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration</i> , 28(5) Journal of Veterinary Pharmacology and Therapeutics 453 (2005)
2015	Yamamoto <i>et al.</i> , <i>Absorption of water-soluble compounds with different molecular weights and [Asu¹⁻⁷]-eel calcitonin from various mucosal administration sites</i> , 76 J. Controlled Release 363 (2001)
2016	Amir H. Shojaei, <i>Buccal Mucosa as a Route for Systemic Drug Delivery: A Review</i> , 1(1) J. Pharmacy & Pharmaceutical Sci. 15 (1998)
2017	Rakesh Hooda <i>et al.</i> , <i>A Review on Oral Mucosal Drug Delivery System</i> , 1(1) Pharma Innovation 14 (2012)
2018	N.V. Satheesh Madhav, <i>Orotransmucosal Drug Delivery Systems: A Review</i> , 140 J. Controlled Release 2 (2009)
2019	U.S. Patent No. 7,331,251
2020	Swatantra K.S. Kushwaha <i>et al.</i> , <i>Advances in Nasal Trans-Mucosal Drug Delivery</i> , 1(7) J. Applied Pharmaceutical Sci. 21 (2011)
2021	Javier O. Morales & Jason T. McConville, <i>Manufacture and Characterization of Mucoadhesive Buccal Films</i> , 77 Eur. J. Pharmaceutics and Biopharmaceutics 187 (2011)
2022	Thakur Smriti, <i>Mouth Dissolving Films: A Review</i> , 4(1) Int'l J. Pharma and Bio Sciences P-899 (2013)
2023	Heiko Tietgen, <i>Physicochemical Properties, in Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays</i> 399 (Hans Gerhard Vogel <i>et al.</i> eds., 2006)
2024	Ulrika Espefalt Westin, <i>Olfactory Transfer of Analgesic Drugs After Nasal Administration</i> (Dissertation, Uppsala University 2007)

Exhibit	Description
2025	Ulrike Werner, <i>In Situ Gelling Nasal Inserts for Prolonged Drug Delivery</i> (Dissertation, Free University Berlin 2003)

TABLE OF CONTENTS

I.	Introduction	1
II.	Development Of The Inventions And The '832 Patent	5
	A. The '832 Patent Solved a Problem with Existing Suboxone® Tablets by Creating a Mucoadhesive Orally-Disintegrating Film.....	5
	B. When the '832 Patent Was Filed in 2009, Oral Transmucosal Delivery Films Were Considered A Pioneering Technology That Was Not Well Defined.....	7
	C. The Inventors of the '832 Patent Surprisingly Discovered That Buprenorphine Absorption Does Not Follow Well-Established pH Partition Theory.....	9
	1. Weinberg (1988)	12
	2. Mendelson (1997)	13
	3. Hao (2003)	14
	4. Robertson (2005).....	16
	5. Batheja (2007).....	16
III.	Claim Construction Under “Broadest Reasonable Interpretation”	17
IV.	Petitioners Fail To Show A Reasonable Likelihood That Any Challenged Claim Of The '832 Patent Is Unpatentable	18
	A. Petitioners Fail To Disclose Any Reference That Teaches A Buffer To Provide A Local pH Of About 3.0 To About 3.5.....	18
	1. Exhibits 1008 and 1009 Do Not Teach or Suggest The Buffer and Local pH Limitations.....	19
	2. Petitioners’ Remaining Arguments Do Not Remedy the Fatal Deficiencies of Exhibits 1008 and 1009	21
	a) pH Tests of Suboxone® Tablets.....	22
	b) Published Buffer Tables	22

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.